POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2 (5α-Reductase Type II) GENES IN PROSTATE CANCER
İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4
*Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26; E-mail: muzeyyenizmirli@gmail.com.
page: 31

REFERENCES

1. Simard J, Dumont M, Labuda, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. 2003; 10(2): 225-259. 2. Takaku H, Minagawa W, Takagi M, Nashimot M. The N-terminal half-domain of the long form of tRNase Z is required for the Rnase 65 activity. Nucleic Acids Res. 2004; 32(15): 4429-4438. 3. Kover W, Guevara C, Chen, Y. Neuteboom S, Bookstein R, Tavtigian S, Lees E. The product of candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex. Int. J Cancer. 2003; 104(3): 283-288. 4. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin A, Nathanson KL, Wein AJ, Malkowicz B. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000; 67(4): 1010-1019. 5. Thigpen AE, Cala KM, Russell DW. Characterization of Chinese hamster ovary cell lines expressing human steroid 5α-reductase isozymes. J Biol Chem. 1993; 268 (23): 17404-17412. 6. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995; 55(18): 3973-3975. 7. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JKV. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 1997; 57(6): 1020-1022. 8. Labrie F, Sagimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N. Structure of human type II 5α-reductase gene. Endocrinology. 1992; 131(3): 1571-1573. 9. Jaffe JM, Malkowicz B, Walker AH, MacBride S, Peschel R, Tomaszewski J, Arsdalen KV, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000; 60(6): 1626-1630. 10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215. 11. Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004; 59(1): 69-76. 12. Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Association of HPC2/ ELAC2 polymorphisms with risk of prostate cancer in a population- based study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9): 876-881. 13. Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and famlial early-onset prostate cancer. Genet Epidemiol. 2005; 28(3): 232-243. 14. Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern- Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis age of onset of disease. Br J Cancer. 2002; 87(8): 905-908. 15. Adler D, Kanji N, Trpkoy K, Fick G, Hughes RM. HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet. 2003; 48(12): 634-638. 16. Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TLJ, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 2001; 61(16): 6038-6041. 17. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schald DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001; 61(17): 6494-6499. 18. Vesprini D, Nam RK, Trachtenberg J, Jewett MAS, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet. 2001; 68(4): 912-917. 19. Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H, Mori M, Naito S. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate. 2004; 61(3): 248-252. 20. Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev. 2001; 23(1): 24-29. 21. Latil AG, Azzouzi R, Cancel GS, Gulllaume EC, Cochan- Priollet C, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001; 92(5): 1130-1137. 22. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JKV. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2001; 10(10): 1077-1082. 23. Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5α-reductase type II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007; 26(2): 100-107. 24. Nam RK, Toi A, Vesprini D, Ho M, Sweet J, Trachtenberg J, Jewett MAS, Narod SA. V89L polymorphism of type-2, 5α-reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001; 57 (1): 199-204. 25. Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D, Rybicki BA. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate. 2007; 67(15): 1654-1663. 26. Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, Ogava O, Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol. 2003; 169(6): 2378-2381. 27. Rajender S, Vuayalakshmi K, Pooja S, Madhavi S, Paul SFD, Vettriselvi V, Shroff S, Singh L, Thangaraj K. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl. 2009; 30(6): 703- 710. 28. Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlen BJ, Rane A. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab. 2001; 86(2): 855-858.



Number 22
VOL. 22, 2019 Accepted articles
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Accepted articles
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006